Nitric oxide and hypercholesterolemia: A matter of oxidation and reduction?

Atherosclerosis

Volumn 137, Issue SUPPL., 1998, Pages

  Wever, Robert ^a   Stroes, Erik ^a   Rabelink, Ton J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; SUPEROXIDE;

ATHEROGENESIS; ATHEROSCLEROSIS; CONFERENCE PAPER; ENZYME ACTIVITY; HUMAN; HYPERCHOLESTEROLEMIA; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANIMALS; HUMANS; HYPERCHOLESTEROLEMIA; NITRATES; NITRIC OXIDE; OXIDATION-REDUCTION;

EID: 0031780095     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00304-3     Document Type: Conference Paper

References (160)

1. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. New Engl J Med 1993;329(27):2002-11.
2. Gimbrone MA. Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis. Am J Cardiol 1995;75:67b-0.
3. Busse R, Fleming I. Regulation and functional consequences of endothelial nitric oxide formation. Ann Med 1995;27:331-40.
4. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:534-6.
5. Anggard E. Nitric oxide: mediator, murderer and medicine. Lancet 1994;343:1199-206.
6. Heitzer T, Yla-Herttuala S, Luoma J, Kurz S, Munzel T, Just H, Olschewski M, Drexler H. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation 1996;93:1346-53.
7. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993;88:2149-55.
8. Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996;94:6-9.
9. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, Deanfield JE. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. New Engl J Med 1996;334:150-4.
10. Seiler C, Hess OM, Buechi M, Suter TM, Krayenbuehl HP. Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries. Circulation 1993;88:2139-48.
11. Creager M, Cooke JP, Mendelsohn ME. Impaired vasodilatation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990;86:228-34.
12. Chowienczyk PJ, Watts GF, Cockroft JR, Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolemia. Lancet 1992;340:1430-2.
13. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992;90:1248-53.
14. McVeigh E, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992;35(8):771-6.
15. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993;88(6):2510-6.
16. Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D'Onofrio F. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997;95(7):1783-90.
17. Clarkson P, Celermajer DS, Donald AE, Sampson M, Sorensen KE, Adams M, Yue DK, Betteridge DJ, Deanfield JE. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 1996;28(3):573-9.
18. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992;90(6):2548-54.
19. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996;27(3):567-74.
20. Egashira K, Suzuki S, Hirooka Y, Kai H, Sugimachi M, Imaizumi T, Takeshita A. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance P. Hypertension 1995;25(2):201-6.
21. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB, Sudano I, Salvetti A. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995;91(7):1981-7.
22. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993;87(5):1468-74.
23. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO III. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 1995;1591(6):1732-8.
24. Quyyumi AA, Mulcahy D, Andrews NP, Husain S, Panza JA, Cannon RO III. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia. Comparison of acetyl-choline and substance P. Circulation 1997;95(1):104-10.
25. Van den Berg M, Boers GHJ, Franken DG, Blom HJ, Kamp GJ, van Jakobs C, Rauwerda JA, Kluft C, Stehouwer CDA. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995;25:176-81.
26. Celermajer DS, Sorensen K, Ryalls M, Robinson J, Thomas O, Leonard JV, Deanfield JE. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993;22(3):854-8.
27. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996;98(1):24-9.
28. Naruse K, Shimizu K, Muramatsu M, Toki Y, Miyazaki Y, Okumura K, Hashimoto H, Ito T. Long-term inhibition of NO-synthesis promotes atherosclerosis in the hypercholesterolaemic rabbit thoracic aorta. Arterioscler Thromb 1994;14:746-52.
29. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994;14:753-9.
30. Numaguchi K, Egashira K, Takemoto M, Kadokami T, Shimokawa H, Sueishi K, Takeshita A. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 1995;26:957-62.
31. Ito A, Egashira K, Kadokami T, Fukumoto Y, Takayanagi T, Nakaike R, Kuga T, Sueishi K, Shimokawa H, Takeshita A. Chronic inhibition of endothelium-derived nitric oxide synthesis causes coronary microvascular structural changes and hyperreactivity to serotonin in pigs. Circulation 1995;92:2636-44.
32. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest 1994;93(1):50-5.
33. Kari JA, Donald AE, Vallance DT, Bruckdorfer KR, Leone A, Mullen MJ, Bunce T, Dorado B, Deanfield JE, Rees L. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int 1997;52:468-72.
34. Reddy KG, Nair RN, Sheehan HM, Hodgson JM. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 1994;23(4):833-43.
35. Luscher TF. The endothelium as target and mediator of cardiovascular disease. Eur J Clin Invest 1993;23:670-85.
36. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995;346:467-71.
37. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997;95(1):76-82.
38. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-31.
39. Vogel RA, Corretti MC, Plotnick GD. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 1996;77:37-40.
40. Vanhoutte PM. Hypercholesterolmia, atherosclerosis and release of endothelium-derived relaxing factor by aggregating platelets. Eur Heart J 1991;12:25-32.
41. Komaru T, Wang Y, Akai K, Sato K, Sekiguchi N, Sugimura A, Kumagai T, Kanatsuka H, Shirato K. Pertussis toxin-sensitive G protein mediates coronary microvascular control during autoregulation and ischemia in canine heart. Circ Res 1994;75:556-66.
42. Gilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA, Cannon RO. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994;90:35-41.
43. Kugiyama K, Kerns SA, Morriset JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990;344:160-2.
44. Flavahan NA. Lysophosphatidylcholine modifies G-protein dependent signaling in porcine endothelial cells. Am J Physiol 1993;264:H722-7.
45. Freeman JE, Kuo WY, Drenger B, Barnett TN, Levine MA, Flavahan NA. Analysis of lysophosphatidylcholine-induced endothelial dysfunction. J Cardiovasc Pharmacol 1996;28:345-52.
46. Davies MG, Ramkumar V, Gettys TW, Hagen PO. The expression and function of G-proteins in experimental intimal hyperplasma. J Clin Invest 1994;94:1680-9.
47. Shibano T, Codina J, Birnbaumer L, Vanhoutte PM. Pertussis toxin-sensitive G-proteins in regenerated endothelial cells of porcine coronary artery. Am J Physiol 1994;267:H979-81.
48. Shimokawa H, Flavahan NA, Vanhoutte PM. Loss of endothelial perfussis toxin-sensitive G-protein function in atherosclerotic coronary arteries. Circulation 1991;83:652-60.
49. Mancusi G, Hutter C, Baumgartner-Parzer S, Schmidt K, Schutz W, Sexl V. High-glucose incubation of human umbilical-vein endothelial cells does not alter expression and function either of G-protein α-subunits or of endothelial NO-synthase. Biochem J 1996;315:281-7.
50. Deckert V, Persegol L, Viens L, Lizard G, Athias A, Lallemant C, Gambert P, Lagrost L. Inhibitors of arterial relaxation among components of human oxidized low-density lipoproteins. Cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium-dependent relaxation. Circulation 1997;95:723-31.
51. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992;90:1168-72.
52. Aji W, Ravalli S, Szabolcs M, Jiang XC, Sciacca RR, Michler RE, Cannon PJ. L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation 1997;95:430-7.
53. Boger RH, Bode-Boger SM, Brandes RP, Phivtongngam L, Bohme M, Nafe R, Mugge A, Frohlich JC. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol fed rabbits. Comparison with lovastatin. Circulation 1997;96:1282-90.
54. Candipan RC, Wang BY, Buitrago R, Tsao PS, Cooke JP. Regression or progression. Dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol 1996;16:44-50.
55. Tsao PS, McEvoy LM, Drexler H, Butcher EC, Cooke JP. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 1994;89:2176-82.
56. Tsao PS, Theilmeier G, Singer AH, Leung LL, Cooke JP. L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb 1994;14:1529-33.
57. Wolf A, Zalpour C, Theilmeier G, Wang BY, Ma A, Anderson B, Tsao PS, Cooke JP. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 1997;29:479-85.
58. Wang BY, Candipan RC, Arjomandi M, Hsiun PT, Tsao PS, Cooke JP. Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits. J Am Coll Cardiol 1996;28:1573-9.
59. Adams MR, McCredie R, Jessup W, Robinson J, Sullivan D, Celermajer DS. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis 1997;129:261-9.
60. Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, McCarthy SN, Keech A, Celermajer DS, Deanfield JE. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996;97:1989-94.
61. Jeremy RW, McCarron H, Sullivan D. Effects of dietary L-arginine on atherosclerosis and endothelium-dependent vasodilatation in the hypercholesterolemic rabbit. Response according to treatment duration, anatomic site and sex. Circulation 1996;94:498-506.
62. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992;90:1248-53.
63. Drexler H, Zeiher A, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine. Lancet 1991;338:1546-50.
64. Dubois-Rande JL, Zelinsky R, Chabrier PE, Castaigne A, Geschwind H, Adnot S. L-arginine improves endothelium-dependent relaxation of conductance and resistance coronary arteries in coronary artery disease. J Cardiovasc Pharmacol 1992;20:S211-3.
65. Egashira K, Katsuda Y, Mohri M, Kuga T, Tagawa T, Kubota T, Hirakawa Y, Takeshita A. Role of endothelium-derived nitric oxide in coronary vasodilatation induced by pacing tachycardia in humans. Circ Res 1996;79:331-5.
66. Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath L, Kleinert H. Nitric oxide synthase isoenzymes. Characterization, purification, molecular cloning and functions. Hypertension 1994;23:1121-31.
67. Simmons WW, Ungureanu-Longrois D, Smith GK, Smith TW, Kelly RA. Glucocorticoids regulate inducible nitric oxide synthase by inhibiting tetrahydrobiopterin synthesis and L-arginine transport. J Biol Chem 1996;271:23928-37.
68. Durante W, Liao L, Iftikhar I, O'Brien W, Schafer AI. Differential regulation of L-arginine transport and nitric oxide production by vascular smooth muscle and endothelium. Circ Res 1996;78:1075-82.
69. Sobrevia L, Yudilevich DL, Mann GE. Activation of A2-purinoceptors by adenosine stimulates L-arginine transport (system y+) and nitric oxide synthesis in human fetal endothelial cells. J Physiol Lond 1997;499:135-40.
70. Vasta V, Meacci E, Maurenzig L, Farnararo M, Bruni P. Agonist-regulated L-arginine uptake in human platelets. Evidence against intracellular utilization of the amino acid. Biochem Mol Biol Int 1996;38:911-9.
71. Chen LY, Mehta P, Mehta JL. Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function. Circulation 1996;93:1740-6.
72. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Gender differences in atherosclerosis: possible role of nitric oxide. J Cardiovasc Pharmacol 1995;26:792-802.
73. Bogle RG, Baydoun AR, Pearson JD, Mann GE. Regulation of L-arginine transport and nitric oxide release in superfused porcine aortic endothelial cells. J Physiol Lond 1996;490:229-41.
74. Bode-Boger SM, Boger RH, Kienke S, Junker W, Frolich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996;219:598-603.
75. Cooke JP, Tsao PS. Arginine: a new therapy for atherosclerosis? Circulation 1997;21(95):311-2.
76. Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, Yasukawa H, Iwami G, Okuda S, Imaizumi T. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 1997;29:242-7.
77. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996;11:2449-52.
78. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
79. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997;95:2068-74.
80. Kimoto M, Whitley GS, Tsuji H, Ogawa T. Detection of NG,NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem Tokyo 1995;117:237-8.
81. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hudson H, Whitley GS, Vallance P. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996;119:1533-40.
82. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992;20:S60-2.
83. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, Luscher T, Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997;99:41-6.
84. Gorren AC, List BM, Schrammel A, Pitters E, Hemmens B, Werner ER, Schmidt K, Mayer B. Tetrahydrobiopterin-free neuronal nitric oxide synthase: evidence for two identical highly antico-operative pteridine binding sites. Biochemistry 1996;35:16735-45.
85. Brand MP, Heales SJ, Land JM, Clark JB. Tetrahydrobiopterin deficiency and brain nitric oxide synthase in the hph1 mouse. J Inherit Metab Dis 1995;18:33-9.
86. Nishimura JS, Martasek P, McMillan K, Salerno J, Liu Q, Gross SS, Masters BS. Modular structure of neuronal nitric oxide synthase: localization of the arginine binding site and modulation by pterin. Biochem Biophys Res Commun 1995;210:288-94.
87. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995;270:319-24.
88. Jessup W. Oxidized lipoproteins and nitric oxide. Curr Opin Lipidol 1996;7:274-80.
89. Hirata K, Miki N, Kuroda Y, Sakoda T, Kawashima S, Yokoyama M. Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res 1995;76:958-62.
90. Zembowicz A, Tang JL, Wu KK. Transcriptional induction of endothelial nitric oxide synthase type III by lysophosphatidylcholine. J Biol Chem 1995;270:17006-10.
91. Li H, Cybulski MI, Gimbrone MA, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine regulated mononuclear adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993;13:197-204.
92. Rosenkranz-Weiss P, Sessa WC, Milstien S, Kaufman S, Watson CA, Pober JS. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity. J Clin Invest 1994;93:2236-43.
93. Yoshizumi M, Perrella MA, Burnett JC, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993;73:205-9.
94. Jia L, Bonaventura J, Stamler JS. S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature 1996;380:221-6.
95. Packer MA, Porteous CM, Murphy MP. Superoxide production by mitochondria in the presence of nitric oxide forms peroxynitrite. Biochem Mol Biol Int 1996;40:527-34.
96. 2 interaction. J Biol Chem 1997;272:9922-32.
97. Darley Usmar V, Halliwell B. Blood radicals: reactive nitrogen species, reactive oxygen species, transition metal ions and the vascular system. Pharm Res 1996;13:649-62.
98. White CR, Brock TA, Chang LY, Crapo J, Briscoe P, Ku D, Bradley WA, Gianturco SH, Gore J, Freeman BA. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA 1994;91:1044-8.
99. Squadrito GL, Pryor WA. The formation of peroxynitrite in vivo from nitric oxide and superoxide. Chem-Biol Interact 1995;96:203-6.
100. Stralin P, Karlsson K, Johansson BO, Marklund SL. The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol 1995;15:2032-6.
101. Halliwell B. Mechanisms involved in the generation of free radicals. Pathol Biol Paris 1996;44:6-13.
102. Czapski G, Goldstein S. The role of the reactions of NO with superoxide and oxygen in biological systems: a kinetic approach. Free Radic Biol Med 1995;19:785-94.
103. Ohara Y, Peterson TE, Sayegh HS, Subramanian RR, Wilcox JN, Harrison DG. Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation 1995;92:898-903.
104. Minor RL, Myers PR, Guerra R, Bates JN, Harrison DG. Diet-induced atherogenesis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest 1990;86:2109-16.
105. Harrison DG, Ohara Y. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: implications for impaired vasomotion. Am J Cardiol 1995;75:75B-81.
106. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546-51.
107. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;93:1107-13.
108. Tilton RG, Kawamura T, Chang KC, Ido Y, Bjercke RJ, Stephan CC, Brock TA, Williamson JR. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest 1997;99:2192-202.
109. Reilly M, Delanty N, Lawson JA, Fitzgerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996;94:19-25.
110. Ting HH, Timimi FK, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation 1997;95:2617-22.
111. Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996;94:6-9.
112. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995;95:187-94.
113. Munzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, Freeman BA, Harrison DG. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 1996;98:1465-70.
114. Holland JA, Pritchard KA, Rogers NJ, Sternerman MB. Perturbation of cultured human endothelial cells by atherogenic levels of low density lipoprotein. Am J Pathol 1988;132:474-8.
115. Pritchard KA, Wong P, Sternerman MB. Atherogenic concentration of low density lipoprotein enhance endothelial cell generation of epoxyeicosatrienoic acid products. Am J Pathol 1990;136:1381-91.
116. Pritchard KA, Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, Wolin MS, Stemerman MB. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995;77:510-8.
117. Marletta MA. Nitric oxide synthase: aspects concerning structure and catalysis. Cell 1994;78:927-30.
118. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls and controls. Cell 1994;78:915-8.
119. Wever RMF, van Dam T, van Rijn HJM, de Groot F, Rabelink TJ. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun 1997;237:340-4.
120. Wang P, Zweier JL. Measurement of nitric oxide and peroxynitrite generation in the postischemic heart. Evidence for peroxynitrite-mediated reperfusion injury. J Biol Chem 1996;271:29223-30.
121. Huk I, Nanobashvili J, Neumayer C, Punz A, Mueller M, Afkhampour K, Mittlboeck M, Losert U, Polterauer P, Roth E, Patton S, Malinski T. L-arginine treatment alters the kinetics of nitric oxide and superoxide release and reduces ischemia/reperfusion injury in skeletal muscle. Circulation 1997;96:667-75.
122. White CR, Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, Parks DA, Tarpey MM, Freeman BA. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci USA 1996;93:8745-9.
123. Cardillo C, Kilcoyne CM, Cannon RO, Quyyumi AA, Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997;30:57-63.
124. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
125. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. Circulation 1995;9:2488-96.
126. Buttery LD, Springall DR, Chester AH, Evans TJ, Standfield EN, Parums DV, Yacoub MH, Polak JM. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 1996;75:77-85.
127. Beckman JS, Koppenol WH. Nitric oxide, superoxide and peroxynitrite: the good, the bad and ugly. Am J Physiol 1996;271:C1424-37.
128. Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol 1995;268:L699-722.
129. Moriel P, Abdalla DS. Nitrotyrosine bound to β-VLDL-apoproteins: a biomarker of peroxynitrite formation in experimental atherosclerosis. Biochem Biophys Res Commun 1997;232:332-5.
130. Leeuwenburgh C, Hardy MM, Hazen SL, Wagner P, Oh ishi S, Steinbrecher UP, Heinecke JW. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem 1997;272:1433-6.
131. Evans P, Kaur H, Mitchinson MJ, Halliwell B. Do human atherosclerotic lesions contain nitrotyrosine? Biochem Biophys Res Commun 1996;226:346-51.
132. Szabo C. The pathophysiological role of peroxynitrite in shock, inflammation and ischemia-reperfusion injury. Shock 1996;6:79-88.
133. Salman Tabcheh S, Guerin MC, Torreilles J. Nitration of tyrosyl residues from extra- and intracellular proteins in human whole blood. Free Radic Biol Med 1995;19:695-8.
134. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD, Beckman JS. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 1992;298:431-7.
135. Szabo C, Zingarelli B, O'Connor M, Salzman AL. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci USA 1996;93:1753-8.
136. Squadrito GL, Pryor WA. The formation of peroxynitrite in vivo from nitric oxide and superoxide. Chem-Biol Interact 1995;96:203-6.
137. Villa LM, Salas E, Darley Usmar VM, Radomski MW, Moncada S. Peroxynitrite induces both vasodilatation and impaired vascular relaxation in the isolated perfused rat heart. Proc Natl Acad Sci USA 1994;91:12383-7.
138. Liu S, Beckman JS, Ku DD. Peroxynitrite, a product of superoxide and nitric oxide, produces coronary vasorelaxation in dogs. J Pharmacol Exp Ther 1994;268:1114-21.
139. Wei EP, Kontos HA, Beckman JS. Mechanisms of cerebral vasodilation by superoxide hydrogen peroxide and peroxynitrite. Am J Physiol 1996;271:H1262-6.
140. Wu M, Pritchard KA Jr, Kaminski PM, Fayngersh RP, Hintze TH, Wolin MS. Involvement of nitric oxide and nitrosothiols in relaxation of pulmonary arteries to peroxynitrite. Am J Physiol 1994;266:H2108-13.
141. Kooy NW, Lewis SJ. The peroxynitrite product 3-nitro-L-tyrosine attenuates the hemodynamic responses to angiotensin II in vivo. Eur J Pharmacol 1996;315:165-70.
142. Lefer DJ, Scalia R, Campbell B, Nossuli T, Hayward R, Salamon M, Grayson J, Lefer AM. Peroxynitrite inhibits leukocyte-endothelial cell interactions and protects against ischemia-reperfusion injury in rats. J Clin Invest 1997;99:684-91.
143. Yin K, Lai PS, Rodriguez A, Spur BW, Wong P. Antithrombotic effects of peroxynitrite: inhibition and reversal of aggregation in human platelets. Prostaglandins 1995;50:169-78.
144. Ku DD, Liu S, Dai J. Coronary vascular and antiplatelet effects of peroxynitrite in human tissues. Endothelium 1995;3:309-19.
145. Wu M, Pritchard KA Jr, Kaminski PM, Fayngersh RP, Hintze TH, Wolin MS. Involvement of nitric oxide and nitrosothiols in relaxation of pulmonary arteries to peroxynitrite. Am J Physiol 1994;266:H2108-13.
146. Kooy NW, Royall JA. Agonist-induced peroxynitrite production from endothelial cells. Arch Biochem Biophys 1994;310:352-9.
147. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. New Engl J Med 1995;332:488-93.
148. Plane F, Jacobs M, McManus D, Bruckdorfer KR. Probucol and other antioxidants prevent the inhibition of endothelium-dependent relaxation by low density lipoproteins. Atherosclerosis 1993;103:73-9.
149. Inoue S, Kawanishi S. Oxidative DNA damage induced by simultaneous generation of nitric oxide and superoxide. FEBS Lett 1995;371:86-8.
150. Gauthier TW, Scalia R, Murohara T, Guo JP, Lefer AM. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:1652-9.
151. Davenpeck KL, Gauthier TW, Lefer AM. Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. Gastroenterology 1994;107:1050-8.
152. Gauthier TW, Davenpeck KL, Lefer AM. Nitric oxide attenuates leukocyte-endothelial interaction via P-selectin in splanchnic ischemia-reperfusion. Am J Physiol 1994;267:G562-8.
153. Sato H, Zhao ZQ, Jordan JE, Todd JC, Riley RD, Taft CS, Hammon JW Jr, Li P, Ma X, Vinten-Johansen J. Basal nitric oxide expresses endogenous cardioprotection during reperfusion by inhibition of neutrophil-mediated damage after surgical revascularization. J Thorac Cardiovasc Surg 1997;113:399-409.
154. de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 1992;85:2284-90.
155. Provost P, Merhi Y. Endogenous nitric oxide release modulates mural platelet thrombosis and neutrophil endothelium interactions under low and high shear conditions. Thromb Res 1997;85:315-26.
156. Marks DS, Vita JA, Folts JD, Keaney JF, Welch GN, Loscalzo J. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest 1995;96:2630-8.
157. Draijer R, Atsma DE, van der Laarse A, van Hinsbergh VW. cGMP and nitric oxide modulate thrombin-induced endothelial permeability. Regulation via different pathways in human aortic and umbilical vein endothelial cells. Circ Res 1995;76:199-208.
158. Cardona-Sanclemente LE, Born GV. Effect of inhibition of nitric oxide synthesis on the uptake of LDL and fibrinogen by arterial walls and other organs of the rat. Br J Pharmacol 1995;114:1490-4.
159. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 1994;267:C1405-13.
160. Dubey RK, Jackson EK, Luscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin 1 receptors. J Clin Invest 1995;96:141-9.